You are here

  • Home
  • Archive
  • Volume 9, Issue 9
  • Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design

Citation Tools

Article menu

This article has a correction. Please see:

XML
Immune cell therapies and immune cell engineering
Original research
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Qin H, Yang L, Chukinas JA, et al
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
Journal for ImmunoTherapy of Cancer 2021;9:e003149. doi: 10.1136/jitc-2021-003149